
LIVN
LivaNova PLC
Company Overview
| Mkt Cap | $2.94B | Price | $55.29 |
| Volume | 392.78K | Change | +3.50% |
| P/E Ratio | 46.5 | Open | $54.15 |
| Revenue | $1.3B | Prev Close | $53.42 |
| Net Income | $63.2M | 52W Range | $32.48 - $58.91 |
| Div Yield | N/A | Target | $69.22 |
| Overall | 59 | Value | 60 |
| Quality | -- | Technical | 58 |
No chart data available
About LivaNova PLC
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products and therapies for neurological and cardiac conditions worldwide. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related accessories. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; and devices that deliver neuromodulation therapy for treating difficult-to-treat depression and drug-resistant epilepsy. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
Latest News
Piper Sandler Remains a Buy on LivaNova (LIVN)
Barclays Sticks to Their Hold Rating for LivaNova (LIVN)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | LIVN | $55.29 | +3.5% | 392.78K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |